Do better: The message to the industry from an analysis of c...
Dr Leeza Osipenko and colleagues analysed the quality of clinical evidence submitted by companies to NICE technology appraisals (TAs) over the last 20 years.
Newsletters and Deep Dive digital magazine
Dr Leeza Osipenko and colleagues analysed the quality of clinical evidence submitted by companies to NICE technology appraisals (TAs) over the last 20 years.
The way HTAs are conducted in Europe is changing. And, if organisations act now to overcome the challenges, they could reap the rewards for years to come.
Healthcare professional (HCP) engagement is a term known to everyone who’s trying to win attention in the domain of pharma.
For the digital health and pharma suppliers we cover, February was a month of changes, with CEOs coming and going (sometimes dramatically), and several other C-Suite and board shake-ups.
In an era where digital transformation is not just a choice, but a necessity, pharmaceutical companies are quickly adapting to meet the needs of their healthcare providers and patients.
Editor's Picks
Newsletters and Deep Dive
digital magazine